Anti-HIV drug update.
There continues to be progress in the development of a number of new anti-HIV drugs. Additional research has focused on optimizing the use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs). This has resulted in studies of dual protease inhibitor combinations, protease inhibitor and NNRTI combinations and now dual NNRTI combinations.
D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019562:Viral Load
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors